Status:
COMPLETED
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
Lead Sponsor:
Novartis Pharmaceuticals
Collaborating Sponsors:
Orion Corporation, Orion Pharma
Conditions:
Parkinson's Disease
Eligibility:
All Genders
30-70 years
Phase:
PHASE3
Brief Summary
The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in ...
Eligibility Criteria
Inclusion
- Clinical diagnosis of idiopathic Parkinson's disease
- Diagnosis of Parkinson's disease for no more than 5 years
Exclusion
- History, signs, or symptoms of atypical or secondary parkinsonism
- Presence at baseline of drug-related wearing-off symptoms, dyskinesia or other motor complications
- Levodopa exposure of more than 30 days or anytime within 8 weeks prior to visit 1
- Other inclusion/exclusion criteria applied to this study.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
747 Patients enrolled
Trial Details
Trial ID
NCT00099268
Start Date
September 1 2004
End Date
November 1 2008
Last Update
April 23 2012
Active Locations (73)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
2
Mayo Clinic
Scottsdale, Arizona, United States, 85259
3
Coastal Neurological Medical Group
La Jolla, California, United States, 92037
4
Keck School of Medicine, Division of Movement Disorders
Los Angeles, California, United States, 90033